Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 25-Aug 4:30 PM ET)
J.P. Morgan Issues a Buy Rating on Ultragenyx Pharmaceutical (RARE)
TipRanks (Tue, 25-Aug 8:27 AM ET)
Globe Newswire (Wed, 19-Aug 5:21 PM ET)
Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
Globe Newswire (Tue, 4-Aug 4:05 PM ET)
Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update
Globe Newswire (Tue, 28-Jul 4:05 PM ET)
Globe Newswire (Wed, 15-Jul 11:33 AM ET)
Globe Newswire (Wed, 8-Jul 9:08 AM ET)
Globe Newswire (Tue, 23-Jun 8:00 AM ET)
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm
PRNewswire (Thu, 4-Jun 4:36 PM ET)
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
Globe Newswire (Wed, 3-Jun 4:30 PM ET)
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Ultragenyx Pharmaceutical trades on the NASDAQ stock market under the symbol RARE.
As of August 28, 2026, RARE stock price declined to $25.61 with 1,412,607 million shares trading.
RARE has a beta of 2.12, meaning it tends to be more sensitive to market movements. RARE has a correlation of 0.17 to the broad based SPY ETF.
RARE has a market cap of $2.52 billion. This is considered a Mid Cap stock.
Last quarter Ultragenyx Pharmaceutical reported $214 million in Revenue and -$.90 earnings per share. This beat revenue expectation by $31 million and exceeded earnings estimates by $.26.
In the last 3 years, RARE traded as high as $60.37 and as low as $18.29.
The top ETF exchange traded funds that RARE belongs to (by Net Assets): XBI, VTI, IWM, VB, VBK.
RARE has underperformed the market in the last year with a price return of -14.9% while the SPY ETF gained +20.1%. However, in the short term, RARE had mixed performance relative to the market. It has outperformed in the last 3 months, returning +9.5% vs +2.8% return in SPY. But in the last 2 weeks, RARE shares have been beat by the market, returning -2.9% compared to an SPY return of -1.1%.
RARE support price is $25.39 and resistance is $27.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RARE shares will trade within this expected range on the day.